Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

NCT ID: NCT01489670

Last Updated: 2014-03-28

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 387 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2011-09-30
• Study Completion Date: 2013-03-31

Brief Summary

This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.

Conditions

Glaucoma, Open-Angle; Ocular Hypertension

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Lumigan® 0.01%

Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.

bimatoprost 0.01% ophthalmic solution

Intervention Type: DRUG

Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.

Interventions

bimatoprost 0.01% ophthalmic solution

Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.

Intervention Type: DRUG

Other Intervention Names

Lumigan® 0.01%

Eligibility Criteria

Inclusion Criteria

• Diagnosis of primary open-angle glaucoma or ocular hypertension
• Lumigan® 0.01% prescribed either as monotherapy or adjunctive to beta-blocker therapy

Exclusion Criteria

• None

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Allergan

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Allergan

Locations

Bülach, Canton of Zurich, Switzerland

Countries

Switzerland

Other Identifiers

MAF/AGN/OPH/GLA/032

Identifier Type: -

Identifier Source: org_study_id